We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-9.00 | -0.63% | 1,413.00 | 1,412.00 | 1,415.00 | 1,433.00 | 1,395.00 | 1,427.00 | 56,148 | 15:15:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 954.05 | 1.91B |
Aquestive Granted Preliminary Injunction
WARREN, N.J., July 16, 2018 /PRNewswire/ -- Aquestive Therapeutics ("Aquestive") announces today that the U.S. District Court for the District of New Jersey has granted Aquestive together with Indivior PLC (LON: INDV) and its U.S. subsidiary, Indivior Inc., a preliminary injunction against Dr. Reddy's Laboratories ("DRL"), mandating the restrictions of the previously entered temporary restraining order (TRO) remain in place. The preliminary injunction prevents DRL from using, selling, offering to sell, or importing its generic buprenorphine/naloxone sublingual film until further order of the district court or of the appellate court. At issue in the underlying preliminary injunction proceedings was, among other things, the infringement of U.S. Patent No. 9,931,305 (known as the "305 patent") by DRL.
Keith J. Kendall, CEO of Aquestive, said: "This decision once again demonstrates the significant value our intellectual property has created for Aquestive, its products and our partners." He added, "We continue to believe that DRL's challenge to our patents is without merit."
About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. For more information, please visit our website, aquestive.com.
Media inquiries:
Christopher Hippolyte
christopher.hippolyte@syneoshealth.com
212-364-0458
Investor inquiries:
Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282
View original content:http://www.prnewswire.com/news-releases/court-ruling-in-favor-of-aquestive-therapeutics-enjoining-dr-reddys-laboratories-from-launching-its-generic-suboxone-product-300681098.html
SOURCE Aquestive Therapeutics
Copyright 2018 PR Newswire
1 Year Indivior Chart |
1 Month Indivior Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions